Andere talen RenovoRx, Inc.

Aandelen

RNXT

US75989R1077

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,243 ^USD	+2,73%		+6,24%	-45,72%

16/04	RenovoRx benadrukt de recente presentatie van een samenvatting van klinische gegevens op de jaarlijkse wetenschappelijke bijeenkomst van de Society of Interventional Radiology in 2024	CI
01/04	RenovoRx, Inc. rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

RenovoRx Regains Compliance with Nasdaq Stockholders Equity Requirement	19/04
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement	18/04
Autonomix Medical Inc Covered in Benzinga Article Highlighting Innovative Nerve Treatment Tech	16/04
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	16/04
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	16/04
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026	15/04
RenovoRx, Inc. announced that it has received $11.136652 million in funding	15/04
RenovoRx Announces $11.1 Million at Market Private Placement	08/04
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024	08/04
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024	05/04
RenovoRx, Inc. announced that it expects to receive $11.136652 million in funding	04/04
RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024	12/03
RenovoRx Highlights Key Leadership Promotions	11/03
RenovoRx Highlights Key Leadership Promotions	08/03
RenovoRx, Inc. Announces Executive Changes, Effective March 1, 2024	23/02
RenovoRx, Inc. Appoints Ronald B. Kocak as Principal Accounting and Financial Officer	09/02
RenovoRx, Inc. Announces Resignation of James Ahlers as Chief Financial Officer	09/02
RenovoRx CEO Issues Letter to Shareholders	06/02
RenovoRx Raises $6.1 Million From Private Placement; Shares Rise	29/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen RenovoRx, Inc.

Aandelen

RNXT

US75989R1077

Andere talen

Filters